TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of an Online Tool (COBPeer) Dedicated to Junior Peer Reviewers for Assessing the Reporting of Randomized Controlled Trial Reports
Brief Summary: The peer review process is a cornerstone of biomedical research publication. Despite being essential, the assessment of the completeness of the reporting and the identification of switched outcomes are not appropriately performed. Furthermore, these tasks do not suppose a high level of expertise and could be performed by junior researchers.

To assess the completeness of reporting and identified switched outcome(s), junior peer reviewers could use a simple online tool (COBPeer) based on the CONSORT (Consolidated Standards of Reporting Trials) 2010 checklist and Elaboration and Explanation publication for reporting parallel-group RCTs. The tool would feature bullet points eliciting the meaning of each checklist item. The aim of this study that will compare the accuracy of junior peer reviewers using the tool to that of usual peer reviewers when evaluating the completeness of reporting and switched of primary outcome(s) in reports of RCTs


Options:
A: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Evaluation of reporting inconsistencies | Arm Label: Control arm; Type: OTHER; Interventions: Behavioral: Standard Peer Review. | Intervention Type: BEHAVIORAL; Name: Evaluation of reporting inconsistencies; Assigned to Arm(s): Intervention arm | Intervention Type: BEHAVIORAL; Name: Standard Peer Review.; Assigned to Arm(s): Control arm
B: Arm Label: SPIRIT checklist plus usual practice; Type: EXPERIMENTAL; Interventions: Other: SPIRIT checklist plus usual practice | Arm Label: Usual practice; Type: OTHER; Interventions: Other: Usual practice | Intervention Type: OTHER; Name: SPIRIT checklist plus usual practice; Assigned to Arm(s): SPIRIT checklist plus usual practice | Intervention Type: OTHER; Name: Usual practice; Assigned to Arm(s): Usual practice
C: Arm Label: USUAL PEER REVIEWER; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COBPeer; Type: EXPERIMENTAL; Interventions: Other: COBPEER | Arm Label: GOLD STANDARD; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: COBPEER; Assigned to Arm(s): COBPeer
D: Arm Label: C-short plus usual practice; Type: EXPERIMENTAL; Interventions: Other: C-short plus usual practice | Arm Label: Usual practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: C-short plus usual practice; Assigned to Arm(s): C-short plus usual practice

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High-flow Nasal Cannula Oxygen Therapy With or Without Non-invasive Ventilation (NIV) During the Weaning Period: a Multicenter Randomized Controlled Trial
Brief Summary: Prospective multicenter randomized controlled open-label trial comparing 2 strategies of oxygenation during the post-extubation period in ICU patients at high risk of extubation failure. Patients will be randomized and assigned to one of the two groups, with a 1:1 ratio.


Options:
A: Arm Label: Optiflow then CPAP; Type: EXPERIMENTAL; Interventions: Procedure: O2stand, Procedure: CPAP, Procedure: Optiflow | Arm Label: CPAP then Optiflow; Type: EXPERIMENTAL; Interventions: Procedure: O2stand, Procedure: CPAP, Procedure: Optiflow | Intervention Type: PROCEDURE; Name: O2stand; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP | Intervention Type: PROCEDURE; Name: Optiflow; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP
B: Arm Label: NIV/HFNC group; Type: ACTIVE_COMPARATOR; Interventions: Device: NIV/HFNC | Arm Label: HFNC group; Type: EXPERIMENTAL; Interventions: Device: HFNC | Intervention Type: DEVICE; Name: NIV/HFNC; Assigned to Arm(s): NIV/HFNC group | Intervention Type: DEVICE; Name: HFNC; Assigned to Arm(s): HFNC group
C: Arm Label: BIPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Non invasive ventilation (VNI) | Arm Label: OPTIFLOW; Type: EXPERIMENTAL; Interventions: Device: Non invasive ventilation | Intervention Type: DEVICE; Name: Non invasive ventilation (VNI); Assigned to Arm(s): BIPAP | Intervention Type: DEVICE; Name: Non invasive ventilation; Assigned to Arm(s): OPTIFLOW
D: Arm Label: HFNC alone; Type: ACTIVE_COMPARATOR; Interventions: Device: HFNC | Arm Label: HFNC and NIV; Type: EXPERIMENTAL; Interventions: Device: HFNC, Device: NIV | Intervention Type: DEVICE; Name: HFNC; Assigned to Arm(s): HFNC alone, HFNC and NIV | Intervention Type: DEVICE; Name: NIV; Assigned to Arm(s): HFNC and NIV

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High-flow Nasal Cannula Oxygen Therapy With or Without Non-invasive Ventilation (NIV) During the Weaning Period: a Multicenter Randomized Controlled Trial
Brief Summary: Prospective multicenter randomized controlled open-label trial comparing 2 strategies of oxygenation during the post-extubation period in ICU patients at high risk of extubation failure. Patients will be randomized and assigned to one of the two groups, with a 1:1 ratio.


Options:
A: Arm Label: Standard oxygen therapy; Type: EXPERIMENTAL; Interventions: Device: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand) | Arm Label: nasal high flow oxygen therapy; Type: OTHER; Interventions: Device: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand) | Intervention Type: DEVICE; Name: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand); Assigned to Arm(s): Standard oxygen therapy, nasal high flow oxygen therapy
B: Arm Label: High Flow Conditioned Oxygen Therapy in high risk patients; Type: EXPERIMENTAL; Interventions: Device: High Flow Conditioned Oxygen Therapy in High Risk Patients | Arm Label: Non-invasive mechanical ventilation in High Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Device: Non-invasive mechanical ventilation | Arm Label: High Flow Conditioned Oxygen Therapy in Low Risk Patients; Type: EXPERIMENTAL; Interventions: Device: High Flow Conditioned Oxygen Therapy in High Risk Patients | Arm Label: Conventional Oxygen Therapy in Low Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional Oxygen Therapy | Intervention Type: DEVICE; Name: High Flow Conditioned Oxygen Therapy in High Risk Patients; Assigned to Arm(s): High Flow Conditioned Oxygen Therapy in Low Risk Patients, High Flow Conditioned Oxygen Therapy in high risk patients | Intervention Type: DEVICE; Name: Non-invasive mechanical ventilation; Assigned to Arm(s): Non-invasive mechanical ventilation in High Risk Patients | Intervention Type: DEVICE; Name: Conventional Oxygen Therapy; Assigned to Arm(s): Conventional Oxygen Therapy in Low Risk Patients
C: Arm Label: standard oxygen group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard oxygen | Arm Label: High-flow nasal oxygen (HFNO) group; Type: EXPERIMENTAL; Interventions: Procedure: HFNO | Intervention Type: PROCEDURE; Name: standard oxygen; Assigned to Arm(s): standard oxygen group | Intervention Type: PROCEDURE; Name: HFNO; Assigned to Arm(s): High-flow nasal oxygen (HFNO) group
D: Arm Label: HFNC alone; Type: ACTIVE_COMPARATOR; Interventions: Device: HFNC | Arm Label: HFNC and NIV; Type: EXPERIMENTAL; Interventions: Device: HFNC, Device: NIV | Intervention Type: DEVICE; Name: HFNC; Assigned to Arm(s): HFNC alone, HFNC and NIV | Intervention Type: DEVICE; Name: NIV; Assigned to Arm(s): HFNC and NIV

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stepwise Strategy to Improve Cervical Cancer Screening Adherence (SCAN-CC): Automatic Text Messages, Phone Calls and Face-to-face Interviews
Brief Summary: This study aims to assess the effectiveness of a stepwise approach, with increasing complexity and cost, to improve adherence to organized cervical cancer screening: step 1a - customized text message invitation; step 1b - customized automatic phone call invitation; step 2 - secretary phone call; step 3 - health professionals face-to-face appointment.

A population-based randomized controlled trial will be implemented in Portuguese urban and rural areas. Women eligible for cervical cancer screening will be randomized (1:1) to intervention and control. In the intervention group, women will be invited for screening through text messages, automatic phone calls, manual phone calls and health professional appointments, to be applied sequentially to participants remaining non-adherent after each step. Control will be the standard of care (invitation by written letter).

As primary objectives, we intend to test the superiority of interventions based on step 1 (1a+1b) and multistage interventions based on steps 1 and 2 and steps 1 to 3, based on intention-to-treat analyses.


Options:
A: Arm Label: Control, standard care for HPV vaccine; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention, computer reminder system; Type: EXPERIMENTAL; Interventions: Behavioral: Computer reminder system | Intervention Type: BEHAVIORAL; Name: Computer reminder system; Assigned to Arm(s): Intervention, computer reminder system
B: Arm Label: advisory support; Type: EXPERIMENTAL; Interventions: Behavioral: advisory support | Intervention Type: BEHAVIORAL; Name: advisory support; Assigned to Arm(s): advisory support
C: Arm Label: Stepwise intervention; Type: EXPERIMENTAL; Interventions: Other: Customized text message invitation ( Step 1a), Other: Customized automatic phone call invitation (Step 1b), Other: Secretary phone call (Step 2), Other: Health professional face-to-face appointment (Step 3) | Arm Label: Written Letter; Type: ACTIVE_COMPARATOR; Interventions: Other: Written Letter | Intervention Type: OTHER; Name: Customized text message invitation ( Step 1a); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Customized automatic phone call invitation (Step 1b); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Secretary phone call (Step 2); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Health professional face-to-face appointment (Step 3); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Written Letter; Assigned to Arm(s): Written Letter
D: Arm Label: Text Message; Type: EXPERIMENTAL; Interventions: Other: Text Message | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Text Message; Assigned to Arm(s): Text Message

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stepwise Strategy to Improve Cervical Cancer Screening Adherence (SCAN-CC): Automatic Text Messages, Phone Calls and Face-to-face Interviews
Brief Summary: This study aims to assess the effectiveness of a stepwise approach, with increasing complexity and cost, to improve adherence to organized cervical cancer screening: step 1a - customized text message invitation; step 1b - customized automatic phone call invitation; step 2 - secretary phone call; step 3 - health professionals face-to-face appointment.

A population-based randomized controlled trial will be implemented in Portuguese urban and rural areas. Women eligible for cervical cancer screening will be randomized (1:1) to intervention and control. In the intervention group, women will be invited for screening through text messages, automatic phone calls, manual phone calls and health professional appointments, to be applied sequentially to participants remaining non-adherent after each step. Control will be the standard of care (invitation by written letter).

As primary objectives, we intend to test the superiority of interventions based on step 1 (1a+1b) and multistage interventions based on steps 1 and 2 and steps 1 to 3, based on intention-to-treat analyses.


Options:
A: Arm Label: Cell-phone assisted; Type: EXPERIMENTAL; Interventions: Device: Cell-phone | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Cell-phone; Assigned to Arm(s): Cell-phone assisted
B: Arm Label: Text and Voice Messages; Type: EXPERIMENTAL; Interventions: Behavioral: Text and Voice Messages | Arm Label: Interactive Phone Call; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Phone Call | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text and Voice Messages; Assigned to Arm(s): Text and Voice Messages | Intervention Type: BEHAVIORAL; Name: Interactive Phone Call; Assigned to Arm(s): Interactive Phone Call
C: Intervention Type: BEHAVIORAL; Name: Pulse; Assigned to Arm(s): N/A
D: Arm Label: Stepwise intervention; Type: EXPERIMENTAL; Interventions: Other: Customized text message invitation ( Step 1a), Other: Customized automatic phone call invitation (Step 1b), Other: Secretary phone call (Step 2), Other: Health professional face-to-face appointment (Step 3) | Arm Label: Written Letter; Type: ACTIVE_COMPARATOR; Interventions: Other: Written Letter | Intervention Type: OTHER; Name: Customized text message invitation ( Step 1a); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Customized automatic phone call invitation (Step 1b); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Secretary phone call (Step 2); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Health professional face-to-face appointment (Step 3); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Written Letter; Assigned to Arm(s): Written Letter

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Functional Behavior-based Cognitive-Behavioral Therapy for Obsessive Compulsive Behavior in Children With Autism Spectrum Disorder: A Randomized Controlled Trial
Brief Summary: Individuals with high functioning autism spectrum disorder (ASD) frequently experience obsessions and/or compulsions that are similar to those specified in Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5) criteria for obsessive compulsive disorder (OCD). However, little research exists on effective interventions for OCD symptoms (referred to as OCBs) in ASD. In a randomized controlled trial, a manualized functional behavior-based cognitive-behavior therapy (Fb-CBT) consisting of traditional CBT components (psychoeducation and mapping, cognitive-behavioral skills training, exposure, and response prevention) as well as function-based behavioral assessment will be evaluated. Participants will be assigned randomly to Fb-CBT or treatment as usual (TAU). Primary and secondary outcome measures will be used to evaluate the efficacy of the treatment, and will be administered at pre and post-intervention as well as six month follow-up.


Options:
A: Arm Label: Low-Intensity Therapist Assistance (LTA); Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Teletherapy LTA | Arm Label: Standard Therapist Assistance (STA); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Teletherapy STA | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Teletherapy LTA; Assigned to Arm(s): Low-Intensity Therapist Assistance (LTA) | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Teletherapy STA; Assigned to Arm(s): Standard Therapist Assistance (STA)
B: Arm Label: Fb-Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Functional Behavior-Based Cognitive Behavioral Therapy | Arm Label: Treatment as Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Functional Behavior-Based Cognitive Behavioral Therapy; Assigned to Arm(s): Fb-Cognitive Behavioral Therapy
C: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): Cognitive Behavioral Therapy
D: Arm Label: Cognitive-Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-Behavioral Therapy | Arm Label: Wait-list; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Wait-list | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy; Assigned to Arm(s): Cognitive-Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Wait-list; Assigned to Arm(s): Wait-list

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
Brief Summary: This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp.

Approximately 300 subjects with moderate to severe plaque psoriasis of the scalp will be randomized 2:1 to receive either apremilast 30 mg twice daily (BID) or placebo for the first 16 weeks.


Options:
A: Arm Label: CNTO 1275 45 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 45 mg | Arm Label: CNTO 1275 90 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 90 mg | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: CNTO 1275 45 mg; Assigned to Arm(s): CNTO 1275 45 mg | Intervention Type: DRUG; Name: CNTO 1275 90 mg; Assigned to Arm(s): CNTO 1275 90 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg
B: Arm Label: Secukinumab (AIN457) 75 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 150 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 300 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Placebo s.c.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Secukinumab (AIN457), Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab (AIN457); Assigned to Arm(s): Placebo s.c., Secukinumab (AIN457) 150 mg s.c., Secukinumab (AIN457) 300 mg s.c., Secukinumab (AIN457) 75 mg s.c. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c.
C: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
D: Arm Label: Apremilast 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast 30 mg BID | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Apremilast 30 mg BID, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
Brief Summary: This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp.

Approximately 300 subjects with moderate to severe plaque psoriasis of the scalp will be randomized 2:1 to receive either apremilast 30 mg twice daily (BID) or placebo for the first 16 weeks.


Options:
A: Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept
B: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
C: Arm Label: Apremilast 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast 30 mg BID | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Apremilast 30 mg BID, Placebo
D: Arm Label: AIN457 150 mg - Fixed Interval (FI); Type: EXPERIMENTAL; Interventions: Drug: AIN457 150 mg, Drug: Placebo | Arm Label: AIN457 150 mg - Start of relapse (SoR); Type: EXPERIMENTAL; Interventions: Drug: AIN457 150 mg, Drug: Placebo | Arm Label: AIN457 300 mg - Fixed Interval (FI); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: AIN457 300 mg - Start of Relapse (SoR); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg, Drug: Placebo | Arm Label: AIN457 300 mg - Open Label (OL); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Intervention Type: DRUG; Name: AIN457 150 mg; Assigned to Arm(s): AIN457 150 mg - Fixed Interval (FI), AIN457 150 mg - Start of relapse (SoR) | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg - Fixed Interval (FI), AIN457 300 mg - Open Label (OL), AIN457 300 mg - Start of Relapse (SoR) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150 mg - Fixed Interval (FI), AIN457 150 mg - Start of relapse (SoR), AIN457 300 mg - Start of Relapse (SoR)

Answer: C